CF PHARMTECH (02652): ICF001 expands its indications after obtaining implied approval for clinical trials from the National Medical Products Administration.

CF PHARMTECH (02652) announced that its self-developed long-acting inhalation dry powder candidate ICF001 (the product) has received implicit approval from the National Medical Products Administration of the People's Republic of China (NMPA) to conduct clinical trials for interstitial lung diseases (i.e., idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF)). This approval follows the implicit approval granted for the product in March 2026 for clinical trials related to pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The product is now authorized to conduct clinical research for four indications covering vascular lung diseases and progressive fibrotic lung diseases.